Rising Immunological Disease Cases Fuel Demand For Advanced Treatments And Research: Key Factor Driving The Growth In The Guillain-Barre Syndrome Market

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Expected Guillain-Barre Syndrome Market Size During the Forecast Period?
Recent years have seen robust growth in the Guillain-Barre Syndrome market. The market, which stands at $0.60 billion in 2024, is predicted to rise to $0.64 billion in 2025, registering a compound annual growth rate (CAGR) of 5.9%. Contributing factors to this historical growth include an increased demand for GBS treatments, a rise in viral infections, the expansion of global vaccination drives, a deeper understanding of autoimmune mechanisms, and heightened awareness and diagnostics.

There is a strong anticipated growth for the guillain-barre syndrome market size in the TH*Coming years; it is predicted to reach $0.79 billion by 2029 with a compound annual growth rate (CAGR) of 5.6%. The expected growth during this forecasting period can be associated with the rising incidence of guillain-barre syndrome, escalating influence of climate change, increasing implementation of immunotherapies and drugs, improved diagnostic abilities, and increasing cases of multifocal motor neuropathy. The predicted key trends include sophisticated diagnostic procedures, invention of immunoglobulin treatments, advanced plasmapheresis methods, gene therapy research, greater emphasis on early intervention, discovery of novel prognosis biomarkers, and broader clinical trials for pioneering treatments.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21198

What Are the High-Growth Segments in the Guillain-Barre Syndrome Market?
The guillain-barre syndrome market covered in this report is segmented -

1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), Other Types
2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics
3) By Route Of Administration: Parenteral, Oral
4) By End User: Hospitals, Clinics, Diagnostic Centers, Other End Users

Subsegments:
1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement
2) By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Progressive CIDP, Relapsing-Remitting CIDP, Multifocal CIDP
3) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia
4) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement
5) By Other Types: Acute Sensory Ganglionopathy, Variants With Cranial Nerve Involvement, Bickerstaff Brainstem Encephalitis

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21198&type=smp

What Key Drivers Are Expected to Influence Future Guillain-Barre Syndrome Market Growth?
The escalating threat of immunological disorders is predicted to drive the advancement of the guillain-barre syndrome market in the future. These health conditions, caused by extremely active, passive, or misguided immune systems, result in ailments like autoimmune diseases, allergies, or immunodeficiencies. Activities such as environmental change, lifestyle modifications, effective diagnosis, and inherent genetic susceptibility are what contribute significantly to the surge in these disorders. When an autoimmune response, which mistakenly assaults the peripheral nerves, gets triggered by an immunological disorder, it results in guillain-barré syndrome, causing inflammation and nerve impairment. As an instance, a report released by the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Swiss government institution, reveals that there were approximately 39.5 million people bearing the burden of HIV at the end of 2022, with 1.3 million being new infections and 630,000 being AIDS-related deaths reported in that particular year. The global figure for people enduring HIV had seen a rise to about 39.9 million in 2023. This increasing threat of immunological disorders is, therefore, the primary motivator for the growth in the guillain-barre syndrome market.

Which Companies Hold the Largest Share Across Different Guillain-Barre Syndrome Market Segments?
Major companies operating in the guillain-barre syndrome market are Pfizer Inc., Roche AG, Thermo Fisher Scientific Inc., AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., Annexon Inc., Immunovant Inc., CSL Behring LLC, Hansa Biopharma AB, NeuLine Health Inc., Ridge Diagnostics Inc., Deymed Diagnostic LLC, VYVGART Hytrulo.

What Guillain-Barre Syndrome Market Trends Are Gaining Traction Across Different Segments?
In an effort to increase the effectiveness of treatments, address clinical demands that have not yet been met, and grow their footprint in the guillain-barre syndrome market, leading companies are prioritizing the development of innovative drugs like monoclonal antibodies. These are proteins engineered in a lab to focus on specific antigens, which aids in regulating immune responses and boosting therapeutic results. For example, in October 2023, the European Medicines Agency (EMA) gave Annexon Inc., an American biopharmaceutical firm, orphan drug status for its medication ANX005 meant for guillain-barre syndrome (GBS) treatment. This monoclonal antibody, which targets C1q, has shown initial improvements in muscle strength and a decrease in ventilation necessity compared to IVIg, making it a noteworthy therapeutic progression.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report

What Are the Emerging Geographies for The Guillain-Barre Syndrome Market Growth?
North America was the largest region in the guillain-barre syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Guillain-Barre Syndrome Market?
2. What is the CAGR expected in the Guillain-Barre Syndrome Market?
3. What Are the Key Innovations Transforming the Guillain-Barre Syndrome Industry?
4. Which Region Is Leading the Guillain-Barre Syndrome Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.